Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Clotting factors are proteins in blood plasma that prevent excessive bleeding. They’re essential to the cascade of events cal…
This essential element in the body’s immune response goes by several names, including “Ig” and “antibodies.” This video and Q…
An article, published in the journal Transfusion, analyzed U.S. donors’ self-reported responses about their health.
A plasma-derived medicine helped Misty Wegman’s husband recover following a “widowmaker” heart attack.
As he nears his one-year anniversary as site leader, Abner Garcia-Delgado talked with the Daily Journal about his management …
CSL Behring, which makes medicines for rare bleeding disorders, recently hosted hematology/oncology fellows at an in-person l…
People with rare and serious diseases depend on plasma-derived medicines, which will be impacted by pending legislation in Eu…
A U.S. Health and Human Services campaign keeps it simple with a message for blood and plasma donors: “Donations save lives.”…
Rare disease patient Alice Drennon remembers 2008 because it was the year she had a run of serious infections. Learning the c…
It is not just the liquid component of blood, it’s a means to treat rare and serious medical conditions.
CSL Plasma’s Walt Charles shares the story of a successful attorney – and Mom – who had a life-changing moment of connection …
CSL Plasma’s Exie Mayes manages a CSL Plasma Center in Delaware. Her 7-year-old daughter Eden relies on a plasma-based medici…
Americas
Asia Pacific
Middle East
Europe
